Loading...
Market
What will be Leqembi's market penetration in Europe within a year of approval?
2
Resolution / Starting Odds
High (>20% of target market) • 25%
Moderate (10%-20% of target market) • 25%
Low (1%-10% of target market) • 25%
Negligible (<1% of target market) • 25%
Market reports and sales data from Biogen and Eisai
Story
EMA Recommends Leqembi for Early Alzheimer's in Patients with ApoE4 Gene; Biogen Shares Rise 5%
Nov 14, 2024, 04:16 PM
The European Medicines Agency (EMA) has recommended the approval of Leqembi, a drug developed by Eisai and Biogen, for the treatment of early Alzheimer's disease. This decision comes after the agency initially rejected the treatment months prior. The recommendation was made by the Committee for Medicinal Products for Human Use (CHMP) and pertains specifically to patients with one or no copies of the ApoE4 gene. The drug has been shown to slow cognitive decline in these patients. Following the announcement, Biogen's shares rose by as much as 5%. The final verdict from the European Commission is still pending.
View original story
Similar markets
High uptake (over 10,000 patients) • 25%
Moderate uptake (5,000-10,000 patients) • 25%
Low uptake (1,000-5,000 patients) • 25%
Very low uptake (under 1,000 patients) • 25%
Yes • 50%
No • 50%
More than $500 million • 25%
$300 million to $500 million • 25%
$100 million to $300 million • 25%
Less than $100 million • 25%
Yes • 50%
No • 50%
Below 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
Above 40% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Below 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
Above 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Low (<10%) • 25%
Moderate (10-30%) • 25%
High (30-50%) • 25%
Very High (>50%) • 25%
European Union • 25%
Japan • 25%
Canada • 25%
Other • 25%
